Global leader in spider silk technology launches second facility, advanced diapausing system, and next-gen silk strains

Kraig Biocraft Laboratories, Inc., a pioneer in the development of spider silk materials, has announced a series of groundbreaking initiatives aimed at scaling production and advancing the quality of its revolutionary spider silk fibers.

The company confirmed the launch of a second parallel production facility, the integration of a new diapausing system, and the deployment of three advanced spider silk strains all part of its ambitious production roadmap for 2025 and 2026.

A Leap in Production Capacity

In a strategic move to strengthen its manufacturing capabilities, Kraig Labs has secured a lease for its second production center in Southeast Asia. This facility, designed as a parallel rearing center, will begin parental strain rearing within the next 30 days. The new site is expected to significantly boost production capacity and ensure a more robust and scalable supply chain for spider silk.

“The two separate rearing centers are a major strategy to form a scalable and reliable supply chain that helps meet the growing demand for spider silk,” said Kim Thompson, Founder and CEO of Kraig Labs. “This strategy, crafted by our chief sericulture expert Dr. Kumar, is essential for uninterrupted and expanded commercial production.”

Advancing Spider Silk Innovation

Kraig Labs has also finalized the development of three next-generation spider silk strains, now ready for field deployment. Two of these strains were designed to replace existing parent lines of the company’s BAM-1 hybrid, resulting in improved hybrid vigor and higher silk yields. The third strain supports the production of silkworms for controlled diapause a critical step for producing premium-quality silk.

“Transitioning to a diapausing hybrid system reflects our long-term vision of providing spider silk at commercial scale without compromising quality,” said Jon Rice, COO of Kraig Labs, during his recent visit to the company’s Southeast Asian production center.

Why Diapause Matters

Diapause is a natural winter dormancy period in silkworms, achieved through a 90-day cold treatment of silkworm eggs. This process helps synchronize production cycles and enhances silk quality, enabling Kraig Labs to cater to high-end clients in the luxury apparel and textiles market.

With these advancements, Kraig Labs is poised to solidify its position as a leading innovator in biomaterials and respond to the surging global demand for sustainable, high-performance spider silk.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com